/

ABEO

Abeona Therapeutics Inc.Closed

4.52−0.38 −7.76%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 4.52 +0.09%

Open

4.88

Prev close

4.90

Day range

4.514.88

52-week range

4.007.65

Volume

1.98M1.43×

Mkt cap

258.47M

P/E ttm

—

Fwd P/E

-21.78

EPS ttm

-1.18

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−40.92%

Price Chart

Yahoo Finance · delayed

ABEOOct 13, 2026O 4.88H 4.88L 4.51C 4.52−0.38 (−7.76%)Vol 1.98M

SMA 505.81
SMA 2005.54

1Y change −16.45% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ABEO Abeona Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −9.78%
1 month: −16.61%
3 months: −35.98%
6 months: −12.91%
Year to date: −14.23%
1 year: −16.45%

Valuation & ownership

Market cap: 258.47M
Enterprise value: 131.52M
P/E (ttm): —
Forward P/E: -21.78
PEG ratio: —
Price / book: 2.02
Price / sales (ttm): 10.13
EV / EBITDA: -1.63
EPS (ttm): -1.18
EPS (forward): -0.2075
Beta (5y monthly): 1.30
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 57.18M
Float: 36.85M
Short % of float: 31.69%
Short ratio (days): 12.15
Held by insiders: 10.96%
Held by institutions: 74.90%
Avg volume (3m): 1.38M
50-day average: 5.85
200-day average: 5.55
52-week change: −16.45%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 25.3
vs 50-day SMA: −22.26%
vs 200-day SMA: −18.44%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.96%
Realised vol (20d, ann.): 45.6%
From 52-week high: −40.92%
From 52-week low: +13.00%

ANR

Analyst Consensus

8 analysts

Consensus

—

Mean target

18.88

+317.59% implied

Low 14.00Median 17.00High 30.00

Recommendation trend

Now7 / 0 / 0
1m ago6 / 0 / 0
2m ago

DES

About Abeona Therapeutics Inc.

Yahoo Finance profile

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Sector: Healthcare
Industry: Biotechnology
Employees: 226
Headquarters: Cleveland, OH, United States
Website: abeonatherapeutics.com
Officers: Dr. Vishwas Seshadri M.B.A., Ph.D. President, CEO & Director
Mr. Joseph Walter Vazzano CPA Chief Financial Officer
Dr. Brendan M. O'Malley J.D., Ph.D. Chief Legal Officer
Mr. Brian Kevany Ph.D. Chief Technical & Scientific Officer

SEAS

Seasonality · ABEO

2007–2026 · monthly returns

Strongest month Feb +15.59%Weakest month Dec −12.74%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.4	0.6	-12.5	21.9	5.9	6.9	3.9	-8.9	-10.3	-13.9			−14.2%
2025	-0.5	-5.4	-9.2	37.8	-4.9	-9.0	12.1	7.2	-22.7	-8.9	5.4	3.9	−5.4%
2024	-18.8	69.5	5.1	-42.9	5.8	-3.2	15.6	16.3	10.9	1.4	-0.3	-12.8	+11.2%
2023	-18.2	-9.1	23.1	8.9	0.7	30.4	-15.1	29.5	-5.0	-9.3	25.7	4.4	+62.7%
2022	-23.5	0.0	23.1	-34.4	-19.0	23.5	-24.6	-8.1	-16.5	51.0	-18.1	-18.1	−63.8%
2021	21.7	26.7	-22.3	-5.9	-6.8	-5.5	-21.8	8.2	-15.2	-27.7	-14.8	-50.7	−78.3%
2020	-33.6	41.9	-31.8	13.3	39.1	-11.8	-2.4	-17.5	-56.6	4.9	51.4	-3.1	−52.0%
2019	-4.9	3.4	4.8	4.6	-29.4	-12.1	-45.8	-40.5	46.8	4.9	42.2	-3.0	−54.2%
2018	-3.8	-9.2	3.6	21.6	1.4	-9.6	-9.7	6.6	-16.9	-32.8	-4.7	-12.9	−55.0%
2017	-5.2	17.4	-7.4	13.0	-5.3	19.6	32.0	55.6	29.7	5.3	-3.6	-8.4	+226.8%
2016	-22.3	-14.2	14.3	6.3	7.4	-19.2	14.0	50.9	47.8	9.2	-4.6	-22.4	+44.3%
2015	-9.0	5.1	-4.8	-10.5	179.4	-35.5	27.5	-27.6	-13.3	-2.5	17.7	-27.7	−2.6%
2014	44.0	8.3	41.0	-14.5	-8.5	-30.2	-13.3	26.9	-15.2	-28.6	-29.9	-50.8	−72.4%
2013	104.2	0.0	0.0	2.0	0.0	-4.0	-16.7	-20.0	40.6	-28.9	-6.3	-16.7	+4.2%
2012	-4.9	0.7	-18.1	-3.5	-10.1	-33.7	12.3	-9.6	-31.8	-22.2	-8.6	-25.0	−83.3%
2011	0.4	-11.6	0.5	4.1	-2.2	-8.9	11.7	-13.5	3.5	-13.7	-24.9	8.3	−41.9%
2010	-15.2	-3.9	-6.3	5.2	-11.0	-16.6	-0.5	4.6	-4.4	53.8	-3.3	-14.5	−24.6%
2009	-9.1	55.6	17.9	-9.1	23.3	21.6	100.0	-15.3	-25.2	5.3	4.0	5.4	+232.3%
2008	-13.8	-19.6	-33.3	70.0	27.5	-13.8	7.1	3.3	-9.7	-33.9	-43.2	-5.7	−69.5%
2007	5.4	140.7	-4.9	-25.9	-4.8	5.0	-12.0	-21.6	29.0	-31.5	-1.0	7.6	+16.1%

INSD

Insider Activity · ABEO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

500 shares

Sells, 6 months

368.2K shares

Net shares

−367.7K

Net change in insider shares

−5.50%

Date	Insider	Transaction	Shares	Value
Sep 28, 2026	Vazzano Joseph WalterChief Financial Officer	Sale at price 5.16 per share.	9.2K	$47.38K
Sep 28, 2026	Seshadri VishwasChief Executive Officer	Sale at price 5.16 per share.	19.6K	$101.09K
Sep 28, 2026	O'Malley Brendan MOfficer	Sale at price 5.16 per share.	6.7K	$34.68K
Sep 28, 2026	Vasanthavada MadhavOfficer	Sale at price 5.16 per share.	4.9K	$25.27K
Aug 31, 2026	Alvino Mark J.Director	Sale at price 5.86 per share.	15K	$87.97K
Jul 20, 2026	Vazzano Joseph WalterChief Financial Officer	Sale at price 6.53 per share.	1.5K	$9.65K
Jul 8, 2026	Vazzano Joseph WalterChief Financial Officer	Sale at price 6.96 per share.	24.9K	$173.26K
Jul 8, 2026	Seshadri VishwasChief Executive Officer	Sale at price 6.96 per share.	68K	$473.33K
Jul 8, 2026	O'Malley Brendan MOfficer	Sale at price 6.96 per share.	12.1K	$83.91K
Jul 8, 2026	Vasanthavada MadhavOfficer	Sale at price 6.96 per share.	12.6K	$87.78K
Jun 29, 2026	Alland LeilaDirector	Sale at price 5.92 per share.	11K	$65.09K
Jun 14, 2026	Silverstein Christine BerniDirector	Sale at price 5.71 per share.	18.2K	$103.69K
Jun 8, 2026	Vazzano Joseph WalterChief Financial Officer	Sale at price 5.30 - 5.43 per share.	49.3K	$265.24K
Jun 8, 2026	Seshadri VishwasChief Executive Officer	Sale at price 5.30 - 5.43 per share.	56.3K	$301.92K
Jun 8, 2026	O'Malley Brendan MOfficer	Sale at price 5.30 - 5.43 per share.	11.1K	$59.65K
Jun 8, 2026	Vasanthavada MadhavOfficer	Sale at price 5.30 - 5.43 per share.	9.6K	$51.55K
May 25, 2026	Alvino Mark J.Director	Stock Gift at price 0.00 per share.	500	—
May 21, 2026	Alvino Mark J.Director	Sale at price 5.46 per share.	6.5K	$35.46K
May 14, 2026	Crombez Eric M.D.Director	Sale at price 5.53 per share.	26.1K	$144.64K
May 10, 2026	Vasanthavada MadhavOfficer	Sale at price 5.96 per share.	5.5K	$33.07K

ABEO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ABEO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Abeona Therapeutics Inc.

Seasonality · ABEO

Insider Activity · ABEO

Congress Trades · ABEO

Investors Holding ABEO

Investors Holding ABEO

Congress Trades · ABEO

Insider Activity · ABEO

Seasonality · ABEO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Abeona Therapeutics Inc.

Financial Snapshot

Earnings & Dividends

News